Entrada Therapeutics Q1 Revenue $875K, Below Consensus
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 07 2026
0mins
Reports Q1 revenue $875,000, consensus $2.92M. "With the recently announced positive data from Cohort 1 of our ELEVATE-44-201 clinical study, this year has already delivered a significant clinical inflection point. Establishing that ENTR-601-44 demonstrated not only favorable safety and tolerability, but early and differentiated functional benefits at 6 mg/kg, is a clear milestone for the program as well as Entrada's neuromuscular pipeline," said Dipal Doshi, Chief Executive Officer at Entrada Therapeutics. "With cash runway into the third quarter of 2027, we are well positioned to achieve additional clinical inflection points throughout the year, including data from the first participant cohort of the ELEVATE-45-201 study, as well as the open-label and second cohort of the ELEVATE-44-201 study. The Company is also carefully evaluating the optimal timing for initiating the planned clinical studies of ENTR-601-50 and ENTR-601-51."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TRDA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TRDA
Wall Street analysts forecast TRDA stock price to rise
4 Analyst Rating
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 6.820
Low
13.00
Averages
16.50
High
20.00
Current: 6.820
Low
13.00
Averages
16.50
High
20.00
About TRDA
Entrada Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in establishing a class of medicines, which engages intracellular targets. Its Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the delivery of a range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. The Company is advancing a robust development portfolio of genetic medicines for the potential treatment of neuromuscular and inherited retinal diseases, among others. The Company is focused on the development of EEV therapeutics for rare neuromuscular diseases, including Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1). It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1. The Company has advanced two ocular programs into lead optimization for the potential treatment of inherited retinal diseases.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Entrada Therapeutics Under Investigation for Securities Fraud
- Investigation Launched: Pomerantz LLP is investigating Entrada Therapeutics, focusing on whether its executives engaged in securities fraud or other unlawful business practices, highlighting serious concerns among investors regarding corporate governance.
- Clinical Trial Results: On May 7, 2026, Entrada announced preliminary data from the ELEVATE-44-201 clinical study, revealing only a 2.36% increase in dystrophin production, a critical muscle-protecting protein, which is significantly below the levels needed to compete with other treatments in the market.
- Stock Price Plunge: Following the disappointing clinical data, Entrada's stock price fell by $9.18, or 57.27%, closing at $6.85 per share, reflecting a pessimistic outlook from the market regarding the company's future prospects.
- Legal Implications: Pomerantz LLP, a prominent firm in securities class action litigation, may lead to a class action lawsuit against Entrada, further exacerbating the legal and financial risks the company faces.
See More
Entrada Therapeutics Under Investigation for Securities Fraud
- Investigation Launched: Pomerantz LLP is investigating on behalf of Entrada Therapeutics, Inc. investors regarding potential securities fraud or unlawful business practices, with investors encouraged to contact Danielle Peyton to join the class action.
- Clinical Trial Results: On May 7, 2026, Entrada released topline data from the ELEVATE-44-201 clinical study, which, despite being labeled as “positive,” only demonstrated a 2.36% increase in dystrophin production, significantly below the levels needed to compete with other treatments.
- Stock Price Plunge: Following the disappointing clinical trial results, Entrada's stock price fell by $9.18, or 57.27%, closing at $6.85 per share on May 7, 2026, indicating a pessimistic market outlook on the company's future prospects.
- Legal Context: Pomerantz LLP, a prominent firm in securities class action litigation with over 85 years of experience, focuses on advocating for victims of securities fraud and corporate misconduct, having historically recovered multimillion-dollar damages for class members.
See More
Entrada Therapeutics Faces Securities Fraud Investigation
- Securities Fraud Investigation: Pomerantz LLP is investigating whether Entrada Therapeutics and its executives have engaged in securities fraud or other unlawful business practices, which could lead to significant losses for investors.
- Poor Clinical Trial Results: On May 7, 2026, Entrada announced that the topline data from the ELEVATE-44-201 clinical study showed only a 2.36% increase in dystrophin production, far below the levels needed to compete with other treatments, impacting the drug's market viability.
- Stock Price Plunge: Following the disappointing clinical results, Entrada's stock price fell by $9.18, or 57.27%, closing at $6.85 per share, reflecting the market's pessimism regarding the company's future prospects.
- Potential Legal Consequences: As a prominent securities litigation firm, Pomerantz LLP may provide legal support to affected investors, further exacerbating the legal and financial risks faced by the company.
See More
Entrada Therapeutics Under Investigation for Securities Violations
- Legal Investigation Launched: The Schall Law Firm has announced an investigation into Entrada Therapeutics for potential violations of securities laws, focusing on whether the company made false or misleading statements that could affect investor rights.
- Disappointing Clinical Trial Results: On May 7, 2026, Entrada reported 'positive' topline data from the ELEVATE-44-201 clinical study, but the results only indicated a slight increase in a protein critical for muscle protection in Duchenne patients, significantly below the improvement needed for market competitiveness.
- Stock Price Plummets: Following the disappointing clinical data, Entrada's shares fell nearly 57.3% on the same day, reflecting strong investor disappointment regarding the company's future prospects.
- Investor Rights Protection: The Schall Law Firm is urging shareholders who suffered losses to participate in the investigation, emphasizing its expertise in securities class action lawsuits and shareholder rights litigation to provide legal support for investors.
See More
Entrada Therapeutics Under Investigation for Securities Fraud
- Investigation Launched: Pomerantz LLP is investigating Entrada Therapeutics, Inc. for potential securities fraud and other unlawful business practices, highlighting serious concerns among investors regarding corporate governance.
- Clinical Trial Results: On May 7, 2026, Entrada announced that its ELEVATE-44-201 clinical study showed only a 2.36% increase in dystrophin production, a critical muscle protection protein, which is significantly below the levels needed to compete with other treatments, potentially impacting future market competitiveness.
- Stock Price Plunge: Following the disappointing clinical data, Entrada's stock price fell by $9.18, or 57.27%, closing at $6.85 per share, reflecting a pessimistic outlook from the market regarding the company's future prospects.
- Legal Implications: Pomerantz LLP, a prominent firm in securities class action litigation with a long history of recovering multimillion-dollar damages for victims, indicates that this investigation could lead to significant legal consequences for the company.
See More
Investigation into Potential Claims for Entrada Therapeutics Investors
- Investigation Background: Johnson Fistel, PLLP is investigating potential claims against Entrada Therapeutics, focusing on whether executive officers violated federal securities laws, which raises concerns about the company's transparency and governance.
- Clinical Trial Results: On May 7, 2026, Entrada announced topline results from the ELEVATE-44-201 clinical study, claiming positive safety and tolerability; however, the reported 2.36% increase in dystrophin was below expectations, potentially undermining investor confidence.
- Stock Price Volatility: Following the disappointing disclosures, Entrada's stock price sharply declined, resulting in significant investor losses, highlighting the uncertainty surrounding the company's future and the likelihood of increased legal actions.
- Legal Services Offered: Johnson Fistel offers no-cost legal consultations to assist affected investors in recovering losses, demonstrating its expertise in securities fraud and commitment to protecting investor rights.
See More
Entrada Therapeutics Under Investigation for Securities Fraud
- Investigation Launched: Pomerantz LLP is investigating Entrada Therapeutics, focusing on whether its executives engaged in securities fraud or other unlawful business practices, highlighting serious concerns among investors regarding corporate governance.
- Clinical Trial Results: On May 7, 2026, Entrada announced preliminary data from the ELEVATE-44-201 clinical study, revealing only a 2.36% increase in dystrophin production, a critical muscle-protecting protein, which is significantly below the levels needed to compete with other treatments in the market.
- Stock Price Plunge: Following the disappointing clinical data, Entrada's stock price fell by $9.18, or 57.27%, closing at $6.85 per share, reflecting a pessimistic outlook from the market regarding the company's future prospects.
- Legal Implications: Pomerantz LLP, a prominent firm in securities class action litigation, may lead to a class action lawsuit against Entrada, further exacerbating the legal and financial risks the company faces.
See More
Entrada Therapeutics Under Investigation for Securities Fraud
- Investigation Launched: Pomerantz LLP is investigating on behalf of Entrada Therapeutics, Inc. investors regarding potential securities fraud or unlawful business practices, with investors encouraged to contact Danielle Peyton to join the class action.
- Clinical Trial Results: On May 7, 2026, Entrada released topline data from the ELEVATE-44-201 clinical study, which, despite being labeled as “positive,” only demonstrated a 2.36% increase in dystrophin production, significantly below the levels needed to compete with other treatments.
- Stock Price Plunge: Following the disappointing clinical trial results, Entrada's stock price fell by $9.18, or 57.27%, closing at $6.85 per share on May 7, 2026, indicating a pessimistic market outlook on the company's future prospects.
- Legal Context: Pomerantz LLP, a prominent firm in securities class action litigation with over 85 years of experience, focuses on advocating for victims of securities fraud and corporate misconduct, having historically recovered multimillion-dollar damages for class members.
See More
Entrada Therapeutics Faces Securities Fraud Investigation
- Securities Fraud Investigation: Pomerantz LLP is investigating whether Entrada Therapeutics and its executives have engaged in securities fraud or other unlawful business practices, which could lead to significant losses for investors.
- Poor Clinical Trial Results: On May 7, 2026, Entrada announced that the topline data from the ELEVATE-44-201 clinical study showed only a 2.36% increase in dystrophin production, far below the levels needed to compete with other treatments, impacting the drug's market viability.
- Stock Price Plunge: Following the disappointing clinical results, Entrada's stock price fell by $9.18, or 57.27%, closing at $6.85 per share, reflecting the market's pessimism regarding the company's future prospects.
- Potential Legal Consequences: As a prominent securities litigation firm, Pomerantz LLP may provide legal support to affected investors, further exacerbating the legal and financial risks faced by the company.
See More
Entrada Therapeutics Under Investigation for Securities Violations
- Legal Investigation Launched: The Schall Law Firm has announced an investigation into Entrada Therapeutics for potential violations of securities laws, focusing on whether the company made false or misleading statements that could affect investor rights.
- Disappointing Clinical Trial Results: On May 7, 2026, Entrada reported 'positive' topline data from the ELEVATE-44-201 clinical study, but the results only indicated a slight increase in a protein critical for muscle protection in Duchenne patients, significantly below the improvement needed for market competitiveness.
- Stock Price Plummets: Following the disappointing clinical data, Entrada's shares fell nearly 57.3% on the same day, reflecting strong investor disappointment regarding the company's future prospects.
- Investor Rights Protection: The Schall Law Firm is urging shareholders who suffered losses to participate in the investigation, emphasizing its expertise in securities class action lawsuits and shareholder rights litigation to provide legal support for investors.
See More
Entrada Therapeutics Under Investigation for Securities Fraud
- Investigation Launched: Pomerantz LLP is investigating Entrada Therapeutics, Inc. for potential securities fraud and other unlawful business practices, highlighting serious concerns among investors regarding corporate governance.
- Clinical Trial Results: On May 7, 2026, Entrada announced that its ELEVATE-44-201 clinical study showed only a 2.36% increase in dystrophin production, a critical muscle protection protein, which is significantly below the levels needed to compete with other treatments, potentially impacting future market competitiveness.
- Stock Price Plunge: Following the disappointing clinical data, Entrada's stock price fell by $9.18, or 57.27%, closing at $6.85 per share, reflecting a pessimistic outlook from the market regarding the company's future prospects.
- Legal Implications: Pomerantz LLP, a prominent firm in securities class action litigation with a long history of recovering multimillion-dollar damages for victims, indicates that this investigation could lead to significant legal consequences for the company.
See More
Investigation into Potential Claims for Entrada Therapeutics Investors
- Investigation Background: Johnson Fistel, PLLP is investigating potential claims against Entrada Therapeutics, focusing on whether executive officers violated federal securities laws, which raises concerns about the company's transparency and governance.
- Clinical Trial Results: On May 7, 2026, Entrada announced topline results from the ELEVATE-44-201 clinical study, claiming positive safety and tolerability; however, the reported 2.36% increase in dystrophin was below expectations, potentially undermining investor confidence.
- Stock Price Volatility: Following the disappointing disclosures, Entrada's stock price sharply declined, resulting in significant investor losses, highlighting the uncertainty surrounding the company's future and the likelihood of increased legal actions.
- Legal Services Offered: Johnson Fistel offers no-cost legal consultations to assist affected investors in recovering losses, demonstrating its expertise in securities fraud and commitment to protecting investor rights.
See More
